Comments
Drug firm Zydus Cadila on Friday said it has received final approval from the US health regulator to market Exemestane tablets, used for the treatment of breast cancer.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, Zydus Cadila said in a BSE filing. The company said it will manufacture the drug at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
Quoting IMS Health data for August 2018, the company said the estimated sale for Exemestane tablets is $68.6 million. Zydus Cadila has more than 220 approvals and so far has filed over 330 abbreviated new drug applications (ANDAs).
Shares of the company’s listed entity, Cadila Healthcare, were trading 0.13 per cent higher at Rs 383.20 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.